Geron raises $100 million for pipeline development
This article was originally published in Scrip
Executive Summary
The gross proceeds from Geron's public offering this week have reached $100 million following the underwriters' decision to exercise in full their option to purchase an additional 2.6 million shares of common stock at the public offering price of $5.00 per share. Geron said earlier this week that it would offer just under 17.4 million shares, excluding the over-allotment option. The company's share price closed 18% down at $5.00 on 7 December following news of the stock dilution.
You may also be interested in...
UK Reimbursement Decisions Focus Mostly On Cancer
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
Deal Watch: Valeant Sells Off iNova To Finance Debt-Reduction Efforts
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Pfizer/Astellas Amend Trial To Position Xtandi In Early Prostate Cancer
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.